INTERPACE BIOSCIENCES, INC. Income (Loss) from Equity Method Investments
INTERPACE BIOSCIENCES, INC. (IDXGD) reported Income (Loss) from Equity Method Investments of -$266.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-10
- INTERPACE BIOSCIENCES, INC. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$266.00K, a 149.91% decline year-over-year.
- INTERPACE BIOSCIENCES, INC. income (loss) from equity method investments for the quarter ending 2026-03-31 was -$831.00K.
- INTERPACE BIOSCIENCES, INC. income (loss) from equity method investments for the quarter ending 2025-09-30 was -$1.01M.
- INTERPACE BIOSCIENCES, INC. income (loss) from equity method investments for the quarter ending 2025-06-30 was $533.00K.
- INTERPACE BIOSCIENCES, INC. income (loss) from equity method investments for fiscal 2024 was $8.10M, a 189.29% increase from fiscal 2023.
- INTERPACE BIOSCIENCES, INC. income (loss) from equity method investments for fiscal 2023 was $2.80M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$266.00K 10-Q · filed 2026-08-10 | -$1.10M 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | -$831.00K 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | -$1.01M 10-Q · filed 2025-11-12 | -$478.00K derived: sum of 2 quarters · filed 2026-08-10 | -$2.23M 10-Q · filed 2025-11-12 | $10.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $533.00K 10-Q · filed 2026-08-10 | -$1.22M 10-Q · filed 2026-08-10 | $11.96M derived: sum of 3 quarters · filed 2026-08-10 | $10.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$1.75M 10-Q · filed 2026-05-12 | $11.43M derived: sum of 2 quarters · filed 2026-05-12 | $9.67M derived: sum of 3 quarters · filed 2026-05-12 | $7.16M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $13.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $11.42M derived: sum of 2 quarters · filed 2025-11-12 | $8.91M derived: sum of 3 quarters · filed 2025-11-12 | $8.10M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$1.76M 10-Q · filed 2025-11-12 | -$4.27M derived: sum of 2 quarters · filed 2025-11-12 | -$5.08M 10-Q · filed 2025-11-12 | -$3.78M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$2.51M 10-Q · filed 2025-08-07 | -$3.32M 10-Q · filed 2025-08-07 | -$2.02M derived: sum of 3 quarters · filed 2025-08-07 | -$2.02M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$812.00K 10-Q · filed 2025-05-08 | $488.00K derived: sum of 2 quarters · filed 2025-05-08 | $488.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.29M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.30M derived: sum of 2 quarters · filed 2024-04-01 | $2.10M derived: sum of 3 quarters · filed 2024-04-01 | $2.80M 10-K · filed 2024-04-01 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $800.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.50M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.50M 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $700.00K 10-Q · filed 2023-05-12 |